Product
SHINGRIX
4 clinical trials
5 indications
Indication
Herpes ZosterIndication
Allergy and ImmunologyIndication
Coronavirus InfectionIndication
Kidney TransplantIndication
Inflammatory Bowel DiseaseClinical trial
A Phase I, Randomized, Observer-blinded, Positive-Controlled, Dose Escalation Clinical Trial to Assess the Safety and Immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 YearsStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
Training the Innate Immune System Against SARS-COV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents: A Randomized, Doubled-Blinded, Comparative Group Observational StudyStatus: Completed, Estimated PCD: 2021-12-30
Clinical trial
Safety and Immunogenicity of Recombinant Glycoprotein E Herpes Zoster Subunit (HZ/su) Vaccine in Renal Transplant RecipientsStatus: Terminated, Estimated PCD: 2020-08-08
Clinical trial
The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on TofacitinibStatus: Recruiting, Estimated PCD: 2024-06-01